Faeth Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Faeth Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 13, 2026). It closed at $20.10, 49.8% below its 52-week high and below its 200-day average, which is rising.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. More about the company

$20.10

-2.28% today

$519M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is FTH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 49w

S1 13w

S2 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 12w → S2 10w → S3 6w → S4 49w → S1 13w → S2 9w → S3 7w → S2 16w → S3 9w → S2 11w → S3 1w current

Total tracked: 166 weeks across 12 stage runs.

FTH among Biotechnology67th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…67	FTHFaeth Therapeutics, Inc.	Stage 3 · wk 2	92	−36.3%

vs 52W High

-49.8%

$7.89 lo$40.05 hi

49.8% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-19.4%

200 DMA: $24.94 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.83x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-36.3%

-29.0%

-38.4%

YTD

+108.4%

+79.5%

Scan Membership

Breakout Watch

Latest: 2024-04-04

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.83x

2026-10-21S3

Wk 2 · Vol 0.48x

2026-10-20S3

Wk 2 · Vol 2.20x

2026-10-19S3

Wk 1 · Vol 0.96x

2026-10-16S3

Wk 1 · Vol 1.67x

2026-10-15S3

Wk 1 · Vol 0.65x

2026-10-14S3

Wk 1 · Vol 1.16x

2026-10-13S32→3

Wk 1 · Vol 0.97x

2026-10-12S2

Wk 11 · Vol 0.86x

2026-10-09S2

Wk 11 · Vol 0.55x

2026-10-08S2

Wk 11 · Vol 0.96x

2026-10-07S2

Wk 11 · Vol 0.90x

Moving averages & range

50 DMA

$30.45

200 DMA

$24.94

52W High

$40.05

52W Low

$7.89

5D Low

$18.80

Resistance levels (recent highs)

20d High

$29.74

60d High

$40.05

120d High

$40.05

250d High

$40.05

Next resistance

+48.0%

to 20d High

ROE

-195.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.0

Faeth Therapeutics: quick answers

What stage is Faeth Therapeutics in?

As of Oct 22, 2026, Faeth Therapeutics (FTH) is in Stage 3, the topping phase. It entered Stage 3 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Faeth Therapeutics in an uptrend?

Its uptrend has stalled. Faeth Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 19.4% below its 200-day average, which is rising.

How far is Faeth Therapeutics from its 52-week high?

Faeth Therapeutics closed at $20.10 on Oct 22, 2026, 49.8% below its 52-week high of $40.05. Its 52-week low is $7.89.

How has Faeth Therapeutics performed over the past year?

As of Oct 22, 2026, Faeth Therapeutics is up 79.5% over the past year and up 108.4% so far in 2026.

Which sector and industry is Faeth Therapeutics in?

Faeth Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.